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emergency cases were young people under 40 years old. Male patients (53.9%) were 
more than female patients. The frequency of emergency visit is 2.7 average per year, 
male patients get 3.0 visits more than female 2.4 visits. About 33.9% of patients 
at one’s own expense. Diseases in the top five were respiratory disease, trauma, 
digestive system diseases, circulation system disease, urinary diseases, respec-
tively. Respiratory disease was the leading member in the spectrum, accounting 
for 25.5%. Poisoning patients account for 1.6% of all emergency cases. Wounded 
patients mostly centralized from May to August, and the bottom periods of the treat-
ment time appeared in midnight (0:00 – 6:00), accounting for 5.5%. CONCLUSIONS: 
Composition of emergency disease spectrum and characteristics of time distribu-
tion can help to develop new prevention and treatment strategies for improving 
quality and increase efficiency. The treatment for respiratory disease headed the 
list of emergency disease spectrum need to optimize medical resourse utilization 
and process improvement.
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OBJECTIVES: To identify the key trends in healthcare spending in Brazil in 
2015. METHODS: Review of the Ministry of Health (for programs), Ministry of 
Planning (for budget) and Workd Bank (for GDP growth) reports as well as recently 
published financial information on Bloomberg and Valor (Brazilian newspaper) on 
Federal and States spending. RESULTS: The economic program established by the 
Brazilian government forecasts growth will return only in 2016. It is worth remem-
bering that in 2014 the GDP growth in Brazil was very close to nil. In 2015, economists 
expect the GDP increase to be below 1%. The Ministry of Health budget in 2014 
was US$ 45.6 billion vs. 2015: US 41.2 billion, a 9.6% reduction caused by increased 
inflation and the devaluation of the Brazilian real against the American dollar. 
Moreover, with the reduction in the price of oil some states, such as Rio de Janeiro, 
might lose US$ 750 million in royalties. In the private setting, ANS, the Federal 
agency that regulates private payers (HMOS, healthcare insurers, etc.), is getting 
ready this year to work on the update of the Minimum Mandatory Coverage List valid 
January 2016 on. In a sector in which 80% of the health plans are either collective 
(unions) or paid by companies, thus, dependent on the expansion of the economy, 
the willingness to pay for the incorporation of new technologies would probably be 
low. CONCLUSIONS: With a struggling economy ahead and consequently smaller 
budgets, not only does the Federal Government foresee adjustments in public 
spending but also do State Governments. Context indicates that dialogue and flex-
ibility among healthcare players will be needed more than ever.
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OBJECTIVES: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. METHODS: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. RESULTS: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2014), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. CONCLUSIONS: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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OBJECTIVES: Demonstrate possible savings by expanding the responsible use of 
OTCs (over-the-counter or nonprescription drugs) in Brazil in the public perspec-
tive. METHODS: Measure the volume and medical costs on public health system 
emergency and usage of OTC medicines. Data were obtained from the DATASUS 
system (030106006), SIGTAP 3.01.1.1.3, and research CHPA / USA January 2012 and 
adopted the premise of 10% OTC in the treatment of common diseases (common 
flu, allergy, and pain), to identify the average ticket cost on OTC consumption were 
used IMS Health of 2013 data and for absenteeism costs were used the Brazilian 
Ministry of work and IBGE data. RESULTS: It was estimated that 8% (5,101,692) of 
all emergency attendances in SUS 2013 resulted in prescriptions that exhibited 
OTC medicines to treat common diseases, at a cost of 56 million,costs related to 
improductible days at BRL 369 million and expenditure in the acquisition of these 
assessment ranking showed that 46.2% of AEs were classified as probable, 35.9% 
possible and 7.9% certain. Based on severity of the AEs, 59.0% were classified as 
moderate 30.8% severe, 5.1% mild and lethal respectively. 87.2% of the AEs were 
assessed as possibly preventable. Assessment of outcomes showed that 94.9% of 
the patients recovered fully while 5.1% died. The organs/systems mostly involved 
in the adverse events were the CNS (headache, dizziness and body pain, 22.1%), 
cutaneous organ (rashes and itching, 19.6%) and respiratory system (Breathlessness 
and cough, 13.5%) Antihypertensives (76.8%), antibiotics (10%), antiretrovirals (7.7%) 
and cholesterol lowering agents (7.7%) were the most commonly implicated classes 
of drugs. CONCLUSIONS: The study shows that AEs constitute a significant cause 
of hospital admissions and a good number will likely develop during hospitaliza-
tion. Intensive monitoring and evaluation of AEs is feasible and will likely provide 
a clearer picture of clinical outcomes.
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OBJECTIVES: Worldwide, the number of disabled individuals is used as a marker for 
population health status because of high morbidity and mortality burden associated 
with disability. Prior studies, which analyzed racial/ethnic disparities in individu-
als with disability, have limitations in regards to population, scope or were limited 
to individuals with chronic condition. The purpose of this study is to determine 
prevalence of disability in different racial/ethnic groups using a standard framework 
for disability. METHODS: A retrospective cross-sectional study design with data 
from 7,993 individuals aged above 21 years from 2012 National Health Interview 
Survey (NHIS) was adopted. Race/ethnicity was categorized into: 1) White; 2) African 
American; 3) Latino and 4) other. Disability was defined based on a standard set 
of questions about mobility, self-care, and cognition from the “Functioning and 
Disability” supplement of 2012 NHIS and it was grouped as: 1) No disability; 2) 
Moderate disability; and 3) Severe disability. Chi-square tests and multinomial logis-
tic regressions were conducted to examine the association between race/ethnicity 
and disability. RESULTS: There were statistically significant racial/ethnic differ-
ences in disability status; 10.2% Whites, 14.8% African Americans, 8.1% Latino, and 
6.7% other racial minorities had severe disability. Without adjustments for socio-
economic status, African Americans were more likely to have severe disability than 
Whites (AOR= 1.56, 95% CI= 1.24, 1.95) and Latinos were less likely to have severe 
disability (AOR = 0.70, 95% CI= 0.55, 0.90). After adjusting for socio-economic status, 
we did not observe statistically significant differences in disability status among 
African Americans and Whites. After adjusting for presence of chronic conditions, 
statistically significant differences in disability status among Latinos and Whites 
disappeared. CONCLUSIONS: Differences in prevalence of disability between 
African Americans and Whites can be partially explained by low socio-economic 
status of African Americans. Improving socio-economic status of African Americans 
may reduce racial disparities in disability prevalence.
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OBJECTIVES: Track the perceptions of key CER stakeholders about the current and 
future effects of CER on evidence generation and application for health care deci-
sions METHODS: Internet and mail survey of health care stakeholders, including 
government, health plans, researchers, human resources specialists, employers, and 
trade organizations, that are influential in or affected by CER; telephone follow-up to 
maximize response. RESULTS: Two-thirds of CER stakeholders say that the current 
CER evidence base is insufficient to support treatment decisions, but 90 percent 
remain committed to the importance of CER. This fifth survey in a series begun in 
2010 found fewer respondents reporting no short-term effects of CER, but more than 
half of respondents believe that substantial improvement in decision-making based 
on CER will occur over the next 5 years. Almost three-fourths of respondents recog-
nize PCORI’s significance in funding and monitoring new research, nearly double the 
level five years ago. Respondents are more positive about research priorities; nearly 
40 percent believe priorities somewhat/adequately reflect treatment choices faced 
by patients and providers, compared to only 22 percent two years ago. Just 9 percent 
believe that processes for interpreting evidence are fully transparent and objective, 
fewer than in the previous three surveys. Only about 25% of respondents report that 
real-world evidence or evidence about variability in individual patient response is 
being used to support treatment decisions. CONCLUSIONS: In successive surveys, 
CER stakeholders continue to look to a five-year horizon for significant effects from 
CER. They generally view the evidence base as incomplete, recognize the key players 
in generating new evidence, and understand the time needed for research in their 
projections of CER’s impact. The relatively scarce use of real-world evidence and 
evidence about patient variability reflects their views about the completeness of 
the evidence base to support treatment decisions.
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OBJECTIVES: This study is to analyze age, disease category, time of emergency treat-
ment and regularity of visiting doctors in order to realize the distribution of disease 
spectrum and epidemiological analysis in emergency department in the top three 
hospital in China. METHODS: To select 29,654 cases in emergency department of 
hospital database of 2013. The top five emergency diseases were studied by ret-
rospective research. Data analysis was performed with STATA software package. 
ncy department in the top three hospital in China. RESULTS: The majority of the 
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for Essential Health Benefits (EHBs). Primary discussions with US private payers 
and ex-CMS policy experts were conducted to understand key issues for medical 
products. RESULTS: The ACA has introduced major changes for product pricing, 
deductible, coverage and uptake. For pricing, major changes are a 50% discount for 
Part D population and an increased rebate of 23.1% for the Medicaid population. 
For deductibles, the patient costs are capped at $12,700. For uptake, an additional 
population is eligible based on expanded access to 30 million uninsured Americans, 
with more than half of them being under the age of 35 years (~59%). For access, 
the 2014 definition of Essential Drug Benefits is likely to either expand or reduce 
coverage depending upon the state and class of drugs. For example, for NSAIDs 
in CA only 20 drugs are covered, while in NY, 40 drugs are covered. During 2012-
2014 Accountable Care Organizations (ACOs) have increased to ~600 organizations 
covering ~18 million lives, which has created a new stakeholder of an integrated 
provider-payer partnership. CONCLUSIONS: ACA has introduced major changes 
which will have a significant impact on converge, pricing and access of pharma-
ceutical and device products.
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OBJECTIVES: Determine if EU pricing and reimbursement (P&R) bodies have revised 
their P&R approval processes for biosimilar medicines to enable faster access and 
optimize the potential healthcare savings. This study analyzed the biosimilar P&R 
procedures across Europe to determine how these differed to the standard and 
generic P&R approval processes. METHODS: OECD pharmaceutical spend data 
across Europe was utilized to identify the European countries that account for 90% 
of EU pharmaceutical spend. The official P&R websites for these 12 countries (France, 
Germany, Italy, Spain, UK, Austria, Poland, Belgium, Netherlands, Sweden, Greece, 
and Switzerland) were identified and analyzed to determine if biosimilar P&R pro-
cess followed the standard, generic or a specific biosimilar P&R approval process. If 
no biosimilar P&R documents were identified, the inference was that they follow the 
standard P&R approval process. RESULTS: Of the 12 countries reviewed, 8 require 
biosimilars to undergo the full standard P&R process, often requiring submission 
of comparative clinical data and development of health economic and/or budget 
impact models. In addition, Switzerland and Spain mandated an additional bio-
similar price discount be applied. 3 markets applied the generic approval process 
to biosimilars, enabling faster access to market. Italy was the only country having a 
specific, abridged biosimilar P&R pathway, where faster access to market is achieved 
if a pre-specified biosimilar price discount, dependent on the sales of the reference 
product, is applied. CONCLUSIONS: In the majority of European countries biosimi-
lars, unlike generics, are still required to undergo a comprehensive standard P&R 
process. Such processes are time consuming, resource intensive and costly for both 
the manufacturers and P&R bodies. The implication is that European payers have 
yet to consider biosimilars to be clinically comparable to their reference products 
or to fully recognise the potential healthcare savings from having an expedited 
biosimilar P&R approval process.
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OBJECTIVES: World Health Organisation (WHO)-CHOICE promotes a threshold 
defined as three times (3x) gross domestic product (GDP) per capita as a guide to deter-
mining cost-effectiveness of health interventions. This analysis sought to evaluate 
the stability of the 3x threshold over time for different countries and the implications 
of this for frequency of requirements to update the threshold value. METHODS: GDP 
per capita data from 2000 to 2014 were taken from the International Monetary Fund 
dataset and used to calculate 3x thresholds for a range of countries considered to be 
representative of different sizes of economies and levels of economic development. 
Proportional changes in the 3x threshold across the entire period and on a year-by-
year basis were analyzed, and time to doubling (and increase by other magnitudes) 
of the initial cost-effectiveness threshold was explored. RESULTS: The 3x threshold 
has increased over the period 2000 to 2014 for 99% of all countries analyzed. The 
average proportional increase in the 3x threshold over this period varied consid-
erably by country, with Belarus having the highest proportional increase over the 
entire time period (94 times). Time to doubling of the 3x threshold was highly variable 
(range 2.1 – 450 years [median 9.1 years]) and was as low as 2 – 3 years for a number 
of countries. High levels of variability were observed between countries within the 
same WHO country groupings. CONCLUSIONS: The results suggest that considerable 
proportional changes to the value of the 3x threshold are observed for a number of 
countries over the short-term. For some countries, the cost-effectiveness threshold 
would be expected to increase dramatically even over a yearly timescale. This research 
highlights the need for countries looking to adopt this threshold to carefully consider 
requirements for updating the threshold and for managing the impact of this, for 
instance in relation to incentives for delayed pharmaceutical entry.
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OBJECTIVES: The objectives of this study were to examine the potential barriers 
to new drug accessibility by exploring factors associated with the marketing lag 
and reimbursement lag, and comparing Taiwan’s approval lag with selected coun-
tries. METHODS: This study focused on new drugs reviewed by Taiwan’s NHI Drug 
Review Committee (DRC) from March, 2001 to December, 2012. Linear regression 
was adopted to estimate factors associated with the marketing lag. A two-part 
drugs at BRL 61 million. CONCLUSIONS: The responsible use of OTC medicines 
can reduce up to 21% the volume of emergency attendances, and for every BRL 1 
spent with OTC drugs is equivalent to an economy of BRL 7 in the public health 
system by reducing emergency visits and improductible days. The self-care, if done 
properly, can be an important factor in the improvement of public health, increas-
ing productivity and reducing costs, in addition to providing more time for health 
professionals in the care of more complex cases. Notwithstanding the expansion 
of OTC drugs usage should be conducted responsibly with quality products and 
effective pharmaceutical care.
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BACKGROUND: Prescription medication adherence is a known health related bar-
rier for elderly patients, leading to insufficient disease control and negative health 
outcomes. Many barriers to prescription adherence have been identified in the litera-
ture, but it is unclear what barriers physicians feel most strongly inhibit adherence 
among patients enrolled in Medicare Advantage Part D (MAPD) plans. OBJECTIVES: 
To identify physician perceived barriers to medication adherence among MAPD 
patients. METHODS: A survey was developed and administered to primary care 
physicians (PCPs) contracted within a MAPD plan in Texas. Surveys were distributed 
during an all-PCP quarterly meeting to increase completion and return rates, and 
were collected prior to the meeting’s conclusion. A free response section was utilized 
for PCPs to indicate up to 3 of the top barriers to medication adherence that they feel 
impact their MAPD patients. Responses were categorized into 8 distinct groups (cost, 
side effects, formulary, lack of patient understanding, forgetfulness, transportation, 
dosage changes, and other). The “other” category encompassed cultural issues, lan-
guage barriers, obtaining drugs out of the country or not using an insurance card, 
and problems at the pharmacy. RESULTS: A total of 210 PCPs (68%) across Texas 
completed and returned the survey. Cost was by far the most commonly identified 
barrier, reported by 77% of respondents. Patient understanding was also a big concern, 
identified by 53% of PCPs. Only 18% of PCPs indicated side effects (actual or potential) 
as a top barrier. Forgetfulness was cited by 22% of PCPs and transportation by 14%. 
Twenty percent of PCP responses fell within the “other” category defined above, while 
formulary (10%) and dosage change (2%) were the least frequently mentioned bar-
riers. CONCLUSIONS: MAPD PCPs most frequently cite financial issues and lack of 
patient understanding as reasons for non-adherence in their patients.
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OBJECTIVES: High risk medication (HRM) use in the elderly is a quality measure 
that contributes to the CMS Star Rating. Various clinical programs to target HRM 
have been described; however, the impact of interventions among the dual eligible 
(DE) Medicare Advantage population is unknown. The objective of this study is to 
compare the impact of a faxed alert intervention directed at HRMs between DE 
and non-DE Medicare Advantage beneficiaries. METHODS: This was a retrospective 
study of pharmacy claims data among Medicare Advantage beneficiaries > 65 years 
of age in 2014. HRMs were defined by industry standard of the American Geriatric 
Society Beers Criteria for Potentially Inappropriate Medication use in Older Adults. 
The HRM Avoidance Program alerts the prescribing provider via fax regarding the 
HRM with recommended alternative(s). Eligible interventions were identified by the 
first HRM fill in the calendar year. Intervention success was defined when a recom-
mended alternative medication was subsequently filled and/or no subsequent fill 
for the same HRM occurred for > 3 months from the index claim date. RESULTS: 
This data represents 926,585 non-DE and 178,840 DE Medicare Advantage benefi-
ciaries. A total of 127,900 pharmacy claims were eligible for the HRM Avoidance 
Program. Of these, 113,627 (89%) were among non-DE and 14,273 (11%) were among 
DE Medicare beneficiaries. The HRM Avoidance Program was successful among 
42% of non-DE compared to 44% of the DE Medicare beneficiaries receiving the 
intervention (p< 0.0001). Significantly higher success rates were observed among 
DE compared to non-DE beneficiaries with the following medication claims: butal-
bital (p= 0.005), carisprodal (p< 0.0001), cyclobenzaprine (p< 0.0001), estrogens 
(p= 0.003), indomethocin (p= 0.001), methocarbamol (p< 0.0001), and promethazine 
(p< 0.0001). CONCLUSIONS: The fax interventions targeting HRM was more success-
ful in the DE than the non-DE Medicare Advantage population. However, further 
research is needed to understand the factors behind the difference in success for 
these populations.
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OBJECTIVES: The Affordable Care Act (ACA) has introduced several major changes 
which can impact product pricing, access and uptake in the United States. The 
objective of this analysis was to review all major new changes due to ACA and 
develop implications for market access for medical products. METHODS: The new 
pricing, access and coverage changes impacting the pharmaceutical and devices 
products were reviewed using the bill for ACA (H. R. 3590), 2011-2013 policy publica-
tions, reports by the Congressional Budget Office and Government Accountability 
Office, and the latest Centers for Medicare & Medicaid Services (CMS) guidelines 
